A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants With AATD Pi*ZZ on WVE-006 (RestorAATion-2)
Latest Information Update: 08 Jun 2026
At a glance
- Drugs WVE-006 (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Adverse reactions
- Acronyms RestorAATion; RestorAATion 2
- Sponsors WaVe life Sciences
Most Recent Events
- 19 May 2026 According to a WaVe life Sciences Media Release, company to host an investor conference call today at 5:30 p.m. ET to review the RestorAATion-2 program and updated clinical data.
- 19 May 2026 According to a WaVe life Sciences Media Release, Data from the RestorAATion-2 clinical trial were also highlighted today at the American Thoracic Society (ATS) International Conference.
- 19 May 2026 Results presented in a WaVe life Sciences Media Release.